Module GLP-31 · Version 1.0
POCT Competency and Continuous Glucose Monitoring
Build the competency and quality controls that keep bedside glucose and continuous glucose monitoring (CGM) results safe to act on: who is authorized to test, what makes a bedside glucose result unreliable, how CGM data reaches the chart, and when a result needs central-lab confirmation before a dose decision is made.
Your next section
Start section 1Read without an account. Sign in to save.
Who this module is for
Laboratory professionals and point-of-care coordinators who train, authorize, or troubleshoot nonwaived point-of-care testing (POCT) operators and hospital CGM workflows.
Learning objectives
- Apply the current six-element CLIA competency framework to nonwaived POCT operators, including timing and who may perform it
- Recognize bedside glucose preanalytical and device limitations, and identify patient states and results that require central-lab confirmation
- Explain CGM data flow, sensor limitations, hospital-use governance, and reconciliation of CGM readings with laboratory and point-of-care methods
How completion works
Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.
Sources
14 sources
1. Centers for Medicare & Medicaid Services. CLIA: Assessing Personnel Competency. Brochure, revised May 2025.
Source note · federal regulation
2. 42 CFR 493.1451, Standard: Technical supervisor responsibilities (competency evaluation, para. (b)(8)-(9)). eCFR, current.
Source note · federal regulation
3. 42 CFR 493.15(e)(1), Laboratories performing waived tests. eCFR, current.
Source note · federal regulation
4. American Diabetes Association. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2026. Diabetes Care 49(Suppl 1):S339.
Source note · professional society guidance
5. American Diabetes Association writing group. Consensus Considerations and Good Practice Points for Use of Continuous Glucose Monitoring Systems in Hospital Settings. Diabetes Care 47(12):2062, 2024.
Source note · professional society guidance
6. US FDA. Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use: Guidance for Industry and FDA Staff. September 2020.
Source note · federal regulation
7. US FDA. Safety communication on GDH-PQQ glucose test strip false elevation with maltose/icodextrin interference.
Source note · federal regulation
8. Clinical and Laboratory Standards Institute. Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline, 3rd ed. CLSI document POCT12-A3. Wayne, PA: CLSI; 2013, reaffirmed 2018.
Source note · consensus standard
9. ISO/TS 22583:2024, Requirements and recommendations for supervisors and operators of point-of-care testing (POCT) equipment. 2nd ed.
Source note · consensus standard
10. College of American Pathologists. Laboratory General Checklist, GEN.54025 Laboratory Personnel Evaluation Roster (Phase II). CAP Accreditation Program, 12.09.2025 edition.
Source note · accreditation standard
11. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring. Pediatr Diabetes, PMC10107687.
Source note · peer-reviewed literature
12. US FDA. Executive summary / 510(k)-DEN review materials on acetaminophen interference for Dexcom G6/G7 and comparator CGM systems.
Source note · federal regulation
13. US FDA. 2024 device clearance summaries: Dexcom Stelo (OTC, March 5, 2024), Dexcom G7 (Feb/Apr 2024), Abbott FreeStyle Libre 3/Libre Rio/Lingo (2024).
Source note · manufacturer labeling
14. Published hospital critical-value lists (e.g., University of Rochester Medical Center and Labcorp critical-value tables) showing adult glucose call thresholds are locally defined.
Source note · laboratory reference